Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
August 22, 2018

MC2 reports positive top-line results from Phase lll psoriasis trial

MC2 Therapeutics has reported positive top-line results from a Phase lll trial to investigate the efficacy and safety of MC2-01 Cream compared to MC2-01 vehicle and Taclonex for the treatment of subjects with psoriasis vulgaris.

MC2 Therapeutics has reported positive top-line results from a Phase lll trial to investigate the efficacy and safety of MC2-01 Cream compared to MC2-01 vehicle and Taclonex for the treatment of subjects with psoriasis vulgaris.

The randomised, multicentre, investigator-blind, parallel-group trial included 796 patients at 55 dermatologists across the US.

During the trial, the patients applied trial medication topically once daily for eight weeks.

The trial’s primary goal was to demonstrate therapeutic non-inferiority of MC2-01 Cream to the active comparator, as well as characterise the safety of MC2-01 Cream in the psoriasis vulgaris patients.

Its primary efficacy endpoint included the proportion of subjects in each treatment group with ‘treatment success’ at week eight, defined as a minimum two-point decrease from baseline in physician global assessment (PGA) score.

The top-line results showed that the trial met its primary goal.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

It was also found that MC2-01 Cream offered a 60.2% reduction in itch at week four as measured by the frequency of a four-grade or greater improvement on an 11-point numeric rating scale of itch severity.

“The significant improvements in both treatment success and patient reported treatment convenience are particularly encouraging.”

The trial reported adverse events that were predictable pharmacological class effects typically associated with calcipotriene and topical corticosteroids.

In addition, the safety profile of MC2-01 cream was found to be similar to that of Taclonex.

The trial lead investigator Linda Stein Gold said: “The significant improvements in both treatment success and patient reported treatment convenience are particularly encouraging.

“Enhanced patient satisfaction enabled by the MC2-01 Cream PAD formulation may increase treatment compliance among patients, and positively impact real-life treatment outcomes even further.

“As such, PAD Technology holds the promise of redefining topicals.”

Psoriasis is a lifelong condition that considerably impacts patients’ quality of life.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU